Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Plans Reverse Stock Split

NEW YORK — OpGen said in a filing with the US Securities and Exchange Commission today that it intends to undertake a 20-for-1 reverse stock split.

The disclosure comes less than a week after the Gaithersburg, Maryland-based developer of antibiotic-resistance testing technology said that it had been notified by the Nasdaq that it was out of compliance with the exchange's $2.5 million minimum shareholder equity requirement and faced delisting.

In the SEC filing, OpGen said that the reverse stock split will become effective on Thursday.

During early afternoon trading Wednesday, shares of OpGen were up nearly 12.5 percent at $.28.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.